Sinopharm Group Co Stock Current Valuation
| X2S Stock | EUR 2.64 0.04 1.54% |
Valuation analysis of Sinopharm Group helps investors to measure Sinopharm Group's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Sinopharm Group's price fluctuation is relatively risky at this time. Calculation of the real value of Sinopharm Group is based on 3 months time horizon. Increasing Sinopharm Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sinopharm stock is determined by what a typical buyer is willing to pay for full or partial control of Sinopharm Group Co. Since Sinopharm Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sinopharm Stock. However, Sinopharm Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.64 | Real 3.03 | Hype 2.64 | Naive 2.77 |
The real value of Sinopharm Stock, also known as its intrinsic value, is the underlying worth of Sinopharm Group Company, which is reflected in its stock price. It is based on Sinopharm Group's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sinopharm Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sinopharm Group Co helps investors to forecast how Sinopharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sinopharm Group more accurately as focusing exclusively on Sinopharm Group's fundamentals will not take into account other important factors: Sinopharm Group Co Company Current Valuation Analysis
Sinopharm Group's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sinopharm Group Current Valuation | 15.96 B |
Most of Sinopharm Group's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sinopharm Group Co has a Current Valuation of 15.96 B. This is 11.11% higher than that of the Healthcare sector and 20.46% higher than that of the Medical Distribution industry. The current valuation for all Germany stocks is 4.0% higher than that of the company.
Sinopharm Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is rated third in current valuation category among its peers.
Sinopharm Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 15.96 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 50.99 % | |||
| Price To Earning | 6.10 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 34.36 B | |||
| Cash Per Share | 11.01 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.93 % | |||
| Current Ratio | 1.29 X | |||
| Book Value Per Share | 21.01 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 0.35 X | |||
| Price To Earnings To Growth | 50.46 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 7.98 B | |||
| Total Asset | 335.41 B | |||
| Z Score | 1.0 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 2.38 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sinopharm Stock
Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.